Did you know that clinical trials with diverse participants provide more broadly applicable and reliable results that help determine whether critical treatments are safe, effective, and can benefit a wide variety of patients?  

For the neuromuscular disease community, clinical trials are one of the most important ways that effective treatments and therapies can reach individuals affected by neuromuscular disease. Researchers need accurate, reliable data to gain a clear understanding of how different patient groups may respond to treatments. Unfortunately, too many clinical trials lack a diverse pool of participants, and many are left out of the process.  

We can change that through H.R. 3503/S. 1701, the NIH Clinical Trial Diversity Act. 

This bipartisan and bicameral legislation would help improve participation in NIH-funded clinical trials to include more diverse patient populations to help ensure that research data and related treatments are safe, effective, and reliable for everyone. 

The NIH Clinical Trial Diversity Act can help strengthen clinical trials by: 

1. Requiring NIH-funded clinical trials to include diverse participants 

2. Providing resources to ensure participation and build trust and awareness 

3. Requiring reporting to monitor progress in expanding clinical trial diversity 

Share this campaign with your family, friends, and colleagues interested in learning more about the importance of diversity in clinical trials. 

Join us in advocating for the NIH Clinical Trial Diversity Act by sending a message to your Members of Congress today!